Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?

Inamura K, Ninomiya H, Ishikawa Y, Matsubara O.

Arch Pathol Lab Med. 2010 Jan;134(1):66-72. doi: 10.1043/2008-0586-RAR1.1. Review.

PMID:
20073607
2.

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.

Diagn Cytopathol. 2007 May;35(5):257-62.

PMID:
17427221
4.

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM.

Clin Cancer Res. 2005 May 15;11(10):3750-7.

7.

Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.

Blons H, Côté JF, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P, Danel C.

Am J Surg Pathol. 2006 Oct;30(10):1309-15.

PMID:
17001163
8.

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.

Taja-Chayeb L, Candelaria M, Brom R, Trejo-Becerril C, Meza F, Duenas-Gonzalez A.

Lung Cancer. 2005 Nov;50(2):259-63. Epub 2005 Jul 11.

PMID:
16009451
9.

A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.

Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, Shimizu S, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Jpn J Clin Oncol. 2006 Feb;36(2):69-75. Epub 2006 Jan 31.

11.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.

J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

12.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.

Cancer Cell. 2006 Jun;9(6):485-95. Epub 2006 May 25.

13.

[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].

de La Motte Rouge T, Valent A, Ambrosetti D, Vielh P, Lacroix L.

Ann Pathol. 2007 Oct;27(5):353-63. French.

PMID:
18185470
14.

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A.

Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. Review.

PMID:
15032719
15.

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule.

Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K, Kohno S.

Lung Cancer. 2008 Apr;60(1):136-40. Epub 2007 Sep 24.

PMID:
17889960
16.

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR, Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, Huang YJ, Liao RQ, Wu YL.

Clin Oncol (R Coll Radiol). 2007 Sep;19(7):499-506. Epub 2007 May 29.

PMID:
17537621
17.

Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

Haneda H, Sasaki H, Shimizu S, Endo K, Suzuki E, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Lung Cancer. 2006 Apr;52(1):47-52. Epub 2006 Feb 28.

PMID:
16503085
18.

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

Prudkin L, Wistuba II.

Ann Diagn Pathol. 2006 Oct;10(5):306-15. Review.

PMID:
16979526
19.

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC.

Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468.

20.

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID:
15075904
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk